Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Bristol-Myers Squibb Co Stock (BMY) Moved Down by 3.58% on Apr 2: What Signal Does It Send?
Bristol-Myers Squibb (BMY) stock decreased by 3.58% on April 2nd due to negative financial reports, lower-than-expected earnings guidance for 2026, and concerns over future revenue declines. The company also faces long-term challenges from patent expirations for key drugs like Eliquis and Opdivo and a significant legal dispute with former Celgene shareholders, alongside substantial long-term debt. Analysts have an average price target of $61.66 for the stock, with a “Hold” rating.